Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Cancer Research
|
August 18, 2010
ZIC1 overexpression is oncogenic in liposarcoma
Elliott Brill, Ryan Gobble, Christina Angeles, et al.
Oncotarget
|
March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Marta Kovatcheva, David D Liu, Mark A Dickson, et al.
Cell Stem Cell
|
January 9, 2009
p53 regulates hematopoietic stem cell quiescence
Yan Liu, Shannon E Elf, Yasuhiko Miyata, et al.
JAMA Oncology
|
April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial
Mark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Molecular and Cellular Biology
|
May 16, 2007
Cooperation between p27 and p107 during endochondral ossification suggests a genetic pathway controlled by p27 and p130
Nancy Yeh, Jeffrey P Miller, Tripti Gaur, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 4, 2005
p130Rb2 and p27kip1 cooperate to control mobilization of angiogenic progenitors from the bone marrow
Anxo Vidal, Stergios Zacharoulis, Wenjun Guo, et al.
Cancer Research
|
September 5, 2006
p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling
James Hulit, Richard J Lee, Zhiping Li, et al.
Pharmacological Reviews
|
March 27, 2025
Cell cycle dysregulation in cancer
Antonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, et al.
Cancer Discovery
|
September 21, 2021
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Qing Li, Baishan Jiang, Jiaye Guo, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Cancer Research
|
August 18, 2010
ZIC1 overexpression is oncogenic in liposarcoma
Elliott Brill, Ryan Gobble, Christina Angeles, et al.
Oncotarget
|
March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Marta Kovatcheva, David D Liu, Mark A Dickson, et al.
Cell Stem Cell
|
January 9, 2009
p53 regulates hematopoietic stem cell quiescence
Yan Liu, Shannon E Elf, Yasuhiko Miyata, et al.
JAMA Oncology
|
April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial
Mark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Molecular and Cellular Biology
|
May 16, 2007
Cooperation between p27 and p107 during endochondral ossification suggests a genetic pathway controlled by p27 and p130
Nancy Yeh, Jeffrey P Miller, Tripti Gaur, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 4, 2005
p130Rb2 and p27kip1 cooperate to control mobilization of angiogenic progenitors from the bone marrow
Anxo Vidal, Stergios Zacharoulis, Wenjun Guo, et al.
Cancer Research
|
September 5, 2006
p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling
James Hulit, Richard J Lee, Zhiping Li, et al.
Pharmacological Reviews
|
March 27, 2025
Cell cycle dysregulation in cancer
Antonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, et al.
Cancer Discovery
|
September 21, 2021
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Qing Li, Baishan Jiang, Jiaye Guo, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Page
of 5